Mostrar el registro sencillo del ítem

dc.contributor.authorBeck, Ekkehard
dc.contributor.authorBiundo, Eliana
dc.contributor.authorDevlin, Nancy
dc.contributor.authorDoherty, T. Mark
dc.contributor.authorGarcía-Ruiz, Antonio J. 
dc.contributor.authorPostma, Maarten
dc.contributor.authorSheikh, Shazia
dc.contributor.authorSmela, Beata
dc.contributor.authorToumi, Mondher
dc.contributor.authorWasem, Jurgen
dc.contributor.authorNolan, Terry
dc.contributor.authorSalisbury, David
dc.date.accessioned2024-02-09T12:12:42Z
dc.date.available2024-02-09T12:12:42Z
dc.date.created2024
dc.date.issued2022-05
dc.identifier.citationBeck, E., Biundo, E., Devlin, N., Doherty, T. M., Garcia-Ruiz, A. J., Postma, M., Sheikh, S., Smela, B., Toumi, M., Wasem, J., Nolan, T., & Salisbury, D. (2022). Capturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual framework. Vaccine, 40(30), 4008–4016es_ES
dc.identifier.urihttps://hdl.handle.net/10630/30293
dc.description.abstractThe objective of this analysis was to focus on health technology assessment systems to identify relevant value concepts in order to improve current EE of non-pandemic vaccines. Methods: Following a literature review, a novel Value of Vaccination (VoV) framework was developed with experts in vaccine EE from developed countries with established health technology assessment systems. Results: Forty-four studies presenting value frameworks or concepts applicable to vaccination were included. Eighteen unique value concepts relevant to EE were identified and defined. These were categorised within the VoV framework using three dimensions, moving from a narrow payer perspective to a more expansive and societal perspective. The dimensions were: (I) conventional payer perspective concepts (e.g., health gains in vaccinees, direct medical costs); (II) conventional societal perspective concepts (e.g., indirect health/economic gains to caregivers/households, productivity in vaccinees); and (III) novel societal concepts (e.g., financial risk protection, peace of mind, societal health gains, healthcare systems security, political stability, social equity and macroeconomic gains). While good quality evidence and methods are available to support concepts in Dimensions I and II, further work is needed to generate the required evidence for vaccination impact on Dimension III concepts. Conclusions: The devastating effect on nations of the COVID-19 pandemic has helped to highlight the potential far-reaching benefits that many vaccination programmes can offer. This VoV framework is particularly relevant to policy decisions considering EE, and the potential future expansion of non-pandemic vaccination value considerations. The framework helps to understand and compare current value considerations across countries and payer versus societal perspectives. It provides decision-makers with a transparent and logical path to broaden consideration of VoV in EE.es_ES
dc.description.sponsorshipGlaxoSmithKline Biologicals SA funded this study (GSK study identifier: VEO-000022/VEO-000023) and all costs related to the development of the publications.es_ES
dc.language.isoenges_ES
dc.publisherElsevieres_ES
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectVacunaciónes_ES
dc.subjectEconomía de la saludes_ES
dc.subject.otherEconomic evaluationes_ES
dc.subject.otherPolicyes_ES
dc.subject.otherVaccinationes_ES
dc.subject.otherValue frameworkes_ES
dc.titleCapturing the value of vaccination within health technology assessment and health economics: Literature review and novel conceptual frameworkes_ES
dc.typejournal articlees_ES
dc.identifier.doi10.1016/j.vaccine.2022.04.050
dc.type.hasVersionVoRes_ES
dc.departamentoFarmacología y Pediatría
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem